— Isabelle Laurence, Adam Hutchings & Elena Nicod
Addressing remaining unmet needs in rare diseases hinges on a positive and enduring policy environment which helps to achieve the necessary clinical and economic conditions for drug development in small, hard-to-treat populations. This white paper examines through historic case analysis the factors which make up those conditions and how these are shaped by policy to encourage (or deter) innovation.
